TRIM22 governs tumorigenesis and protects against endometrial cancer-associated cachexia by inhibiting inflammatory response and adipose thermogenic activity

Table 1 Distribution of the participants and tissue characteristics

Characteristics		Female		TRIM22(\(\bar X\) ± S)	BMI(\(\bar X\) ± S)	p-Value*
	Case (n = 68)	Controls (n = 25)	Totals (n = 93)			p-Value*
	Case (n = 68)	Controls (n = 25)	Totals (n = 93)			TRIM22	BMI
Age(y)						< 0.0001*	0.2975
1–20	-	-	-	-
21–30	-	1	1	-
31–40	1	2	3	42.91 ± 16.20	-
41–50	15	21	36	38.08 ± 16.8	27.28 ± 3.79
51–60	32	1	33	25.47 ± 10.09	25.59 ± 3.17
61–70	18	-	18	24.62 ± 10.63	26.69 ± 4.68
71–80	2	-	2	23.09 ± 10.97	22.39 ± 3.65
Mean(y)	56.83	44.88	50.855
Mini-Max(y)	38–76	22–51	22–76
Histological grade						0.025*	0.0364*
I	24			29.47 ± 5.03	26.83 ± 3.95
II	31			26.49 ± 6.43	27.07 ± 4.08
III	13			23.72 ± 7.73	24.53 ± 3.00
TNM stage						0.006*	0.527
I	20		20	33.07 ± 4.60	25.97 ± 4.64
II	25		25	29.28 ± 5.06	26.81 ± 3.31
III	18		18	18.45 ± 4.97	25.53 ± 3.66
IV	5		5	14.05 ± 5.53	24.4 ± 3.26
Menstrual cycle phase						0.0005*
Proliferative phase		15	15	41.80 ± 13.06
Secretory phase		10	10	57.03 ± 11.32

ISSN: 2049-3002